Ultra, Ultra XC, Ultra Plus XC
Allergan · Decision date Aug 11, 2026
What did the FDA approve?
FDA records P050047/S098 as a supplement to PMA P050047, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 11, 2026.
FDA approval order statement
Approval for using the sodium hyaluronate manufactured from HTLs additional manufacturing line (HTL4) as raw materials for Juvéderm products.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Aug 11, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P050047/S098
- Regulatory pathway
- PMA supplement
- Applicant
- Allergan
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Aug 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
For the original device and its historical approval scope, see PMA P050047. Subsequent supplements may change the device or its indications.
FDA decision timeline
P050047 · Original PMA
JUVEDERM 24HV, JUVEDERM 30 AND JUVEDERM 30HV GEL IMPLANTS
P050047/S098 received
Application receipt date recorded by FDA.
P050047/S105 · Related supplement
Juvéderm Ultra XC, and Juvéderm Ultra Plus XC (hereafter referred to as Ultra XC and Ultra Plus XC)
P050047/S098 · FDA decision
Normal 180 Day Track
P050047/S107 · Related supplement
Juvéderm Ultra XC, and Juvéderm Ultra Plus XC
P050047/S106 · Related supplement
Juvéderm Ultra XC; Juvéderm Ultra Plus XC
Timeline entries are records held by MedtechLedger for P050047. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P050047
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Allergan | PMA approval | Jun 2, 2006 | FDA | |
| Allergan | PMA supplement | Aug 14, 2025 | FDA | |
Juvéderm Ultra XC, and Juvéderm Ultra Plus XCP050047/S107 | Allergan | PMA supplement | Aug 28, 2026 | FDA |
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
saypha ChiQP250021/S001 | Croma-Pharma GmbH | PMA supplement | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Allergan
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2525 Dupont Dr., Irvine, CA, 92612
Sources and methodology
- Original FDA record: P050047/S098
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



